Nandrolone Decanoate Injection: FDA-Approved Indication
Nandrolone decanoate 10 mg injection is FDA-approved specifically for the management of anemia of renal insufficiency (chronic kidney disease), where it increases hemoglobin and red cell mass. 1
Primary FDA-Approved Indication
The only FDA-approved indication for nandrolone decanoate is:
- Anemia of renal insufficiency/chronic kidney disease 1
- Increases hemoglobin levels
- Increases red cell mass
- Note: Surgically anephric patients may be less responsive
FDA-Approved Dosing for Anemia of Renal Disease
Per FDA labeling 1:
- Women: 50-100 mg per week (intramuscular)
- Men: 100-200 mg per week (intramuscular)
- Children (2-13 years): 25-50 mg every 3-4 weeks
- Route: Deep intramuscular injection into gluteal muscle
- Duration: Discontinue if no hematologic improvement within 6 months
- Adjunctive therapy: Adequate iron intake required for maximal response
Evidence Supporting Renal Anemia Use
Research demonstrates that nandrolone decanoate in dialysis patients produces 2:
- Significant increase in lean body mass (+4.5 kg vs +1.9 kg placebo; P=0.005)
- Improved functional status (walking/stair-climbing time improved)
- Increased serum creatinine (suggesting increased muscle mass)
- Well-tolerated over 6 months
Non-FDA Approved Uses (Not Recommended)
Current guidelines explicitly recommend AGAINST routine use of nandrolone for:
COPD/Pulmonary Rehabilitation
Guidelines state: "Current scientific evidence does not support the routine use of anabolic agents in pulmonary rehabilitation for patients with COPD" (Grade 2C). 3 While nandrolone increased lean mass in COPD patients, it did not improve functional outcomes like 6-minute walk distance or respiratory muscle strength.
Cancer Cachexia
ASCO guidelines do not recommend androgens for cancer cachexia. 4 Evidence shows:
- Nandrolone decanoate (200 mg/week) in lung cancer patients showed only a trend toward less weight loss (not statistically significant, P=0.15)
- Fluoxymesterone was less effective than megestrol acetate for appetite stimulation 5, 6
- Insufficient consistent data to recommend currently approved androgenic steroids 5, 6
HIV Wasting
While research showed benefits in HIV wasting (increased lean body mass and quality of life) 7, 8, this is not an FDA-approved indication and should only be considered in specialized settings with appropriate monitoring.
Critical Safety Considerations
Virilization occurs in approximately 50% of patients (mainly hoarseness and hirsutism), with 9% discontinuing treatment for this reason 9. Other concerns include:
- Lipid abnormalities
- Polycythemia (modest hematocrit increase expected)
- Liver function abnormalities
- Potential enhancement of subclinical prostate cancer growth 3
- Documented tumor progression in hormone-sensitive prostate cancer 10
- Impaired spermatogenesis and male reproductive parameters at supraphysiological doses 11
Bottom Line
Nandrolone decanoate should only be prescribed for its single FDA-approved indication: anemia of chronic kidney disease. Use the FDA-approved dosing regimen (50-200 mg/week depending on sex), ensure adequate iron supplementation, monitor hematologic response at 6 months, and discontinue if ineffective. All other uses lack sufficient evidence for routine clinical recommendation and carry significant virilization and other safety risks.